With the ongoing development of various HuR inhibitors (such as MS-444 and CMLD2), it is possible to modulate Wnt signaling in multiple different cancers, suggesting these inhibitors may serve as potential therapeutic agents [50]. Here, ELAVL1 is linked to cancer.